Open AccessHumanized antibodies for antiviral therapy.
Author(s) -
Mfg Co,
Marguerite Deschamps,
Richard J. Whitley,
Cary Queen
Publication year - 1991
Publication title -
proceedings of the national academy of sciences of the united states of america
Language(s) - English
Resource type - Journals
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.88.7.2869
Subject(s) - monoclonal antibody , antibody , virology , humanized mouse , immunogenicity , humanized antibody , herpes simplex virus , biology , neutralization , monoclonal , hypervariable region , virus , glycoprotein , immunology , microbiology and biotechnology , immune system
Antibody therapy holds great promise for the treatment of cancer, autoimmune disorders, and viral infections. Murine monoclonal antibodies are relatively easy to produce but are severely restricted for therapeutic use by their immunogenicity in humans. Production of human monoclonal antibodies has been problematic. Humanized antibodies can be generated by introducing the six hypervariable regions from the heavy and light chains of a murine antibody into a human framework sequence and combining it with human constant regions. We humanized, with the aid of computer modeling, two murine monoclonal antibodies against herpes simplex virus gB and gD glycoproteins. The binding, virus neutralization, and cell protection results all indicate that both humanized antibodies have retained the binding activities and the biological properties of the murine monoclonal antibodies.